Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : GC5131A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
S. Korea's Green Cross seeks phase 2 trials of COVID-19 plasma drug
Details : The Phase II trials of an experimental COVID-19 blood plasma treatment drug would review the safety and efficacy of the drug in 60 domestic patients in five hospitals.
Brand Name : GC5131A
Molecule Type : Large molecule
Upfront Cash : Not Applicable
July 29, 2020
Lead Product(s) : GC5131A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : NK cell therapy,Antibody recruiting molecule
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Kleo Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC)
Details : Kleo's first non-oncology application of its antibody recruiting molecule (ARM™) to be tested in combination with GCLC'S NK cells as a potential COVID-19 therapeutic.
Brand Name : Undisclosed
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 31, 2020
Lead Product(s) : NK cell therapy,Antibody recruiting molecule
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Kleo Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
LOOKING FOR A SUPPLIER?
Reset All
